Ultrasensitive blood test predicts head and neck cancer relapse months earlier
medicalxpress - A new study by investigators from Mass General Brigham Cancer Institute has found that an ultrasensitive blood test called HPV-DeepSeek could help identify which people with HPV-associated head and neck cancer still had cancer cells in their bodies after …
AI Summary: Researchers validated an ultrasensitive HPV whole‑genome sequencing blood assay that detects minimal residual disease after surgery for HPV‑positive head and neck cancer, flagging relapse months before clinical signs. Early detection could enable earlier salvage therapy and closer surveillance, potentially changing follow‑up care and improving outcomes for this patient group.
Related Stories
FDA advisers to evaluate multi-cancer blood test at upcoming meeting / 4 wks
National study to use genetic testing to guide cancer survivor follow-up / 4 months
Air pollution causes detectable blood changes years before lung cancer / 29 days
Repeat PSMA PET scans change prostate cancer care for many patients / 2 months
ctDNA blood test pinpoints who needs chemo after colorectal liver surgery / 2 months
Prosigna-guided OPTIMA trial shows chemo can be safely skipped in many ER+/HER2− breast cancers / 3 months
Liquid biopsy blood test promises personalized lung cancer detection and monitoring / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Drug Pricing, Zoonotic Disease, Mergers and Acquisitions, Drug Development and look for the RSS link.
StackHealth Time Machine